HC Wainwright & Co. maintains Buy rating on Iovance Biotherapeutics, $20 price target
HC Wainwright & Co. maintained their Buy rating on Iovance Biotherapeutics's stock with a price target of $20.00.The price target implies an upside of 82.0% from the Sep 28 close of $10.99.Key takeaways from the analyst noteStrong Revenue Guidance: Iovance Biotherapeutics raised its FY26 total reve…
HC Wainwright & Co. Key takeaways from the analyst noteStrong Revenue Guidance: Iovance Biotherapeutics raised its FY26 total reve…